Glucocorticoids and the cardiovascular system: State of the art

Current Pharmaceutical Design

Volumn 16, Issue 32, 2010, Pages 3574-3585

  Nussinovitch, Udi ^a   de Carvalho, Jozélio Freire ^b   Pereira, Rosa Maria R ^b   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiopulmonary bypass; Cardiovascular disease; Churg Strauss syndrome; Glucocorticoid; Kawasaki disease; Myocardial infarction; Rheumatic fever; Vasospastic angina

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; HEAT SHOCK PROTEIN 72; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHYLPREDNISOLONE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN KINASE B; THALIDOMIDE; VANCOMYCIN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANEURYSM RUPTURE; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; BACTERIAL ENDOCARDITIS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SYSTEM; CARDITIS; CHURG STRAUSS SYNDROME; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ANEURYSM; DIABETES MELLITUS; DRESSLER SYNDROME; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCARDITIS; FRACTURE; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ANEURYSM; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; ISCHEMIC HEART DISEASE; LIBMAN SACK ENDOCARDITIS; LOW DRUG DOSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; NONHUMAN; OBESITY; OSTEOPOROSIS; PERICARDITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE COMPLICATION; PRINZMETAL ANGINA PECTORIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESTENOSIS; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; RISK REDUCTION; SARCOIDOSIS; SIDE EFFECT; STROKE; SUDDEN DEATH; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY; TUBERCULOUS PERICARDITIS; UNSTABLE ANGINA PECTORIS;

EID: 78650877107     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793797870     Document Type: Article

References (174)

1. Chinenov Y, Rogatsky I. Glucocorticoids and the innate immunesystem: crosstalk with the toll-like receptor signaling network. Mol Cell Endocrinol 2007; 275: 30-42.
2. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B,Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-11.
3. Nussinovitch U, Shoenfeld Y. Autoimmune mechanisms in cardio-vascular diseases. Harefuah 2009; 148: 173-176, 210.
4. Nussinovitch U, Shoenfeld Y. Autoimmunity and heart diseases:pathogenesis and diagnostic criteria. Arch Immunol Ther Exp(Warsz) 2009; 57: 95-104.
5. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin indi-cations and mechanisms in cardiovascular diseases. Autoimmun Rev 2008; 7: 445-52.
6. Rook GA. Glucocorticoids and immune function. Baillieres BestPract Res Clin Endocrinol Metab 1999; 13: 567-81.
7. Thiemermann C. Corticosteroids and cardioprotection. Nat Med 2002; 8: 453-5.
8. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecularmechanisms of glucocorticoid action and selective glucocorticoidreceptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.
9. Kovacs WJ. Molecular mechanisms of glucocorticoid action.Up todate; 17.1.2009; online version.
10. Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC. Glucocorticoids for human skin: new aspects of the mechanism ofaction. Skin Pharmacol Physiol 2005; 18: 103-14.
11. Cutolo M, Seriolo B, Pizzorni C, et al. Use of glucocorticoids andrisk of infections. Autoimmun Rev 2008; 8: 153-5.
12. Chen QM, Alexander D, Sun H, et al. Corticosteroids inhibit celldeath induced by doxorubicin in cardiomyocytes: induction of anti-apoptosis, antioxidant, and detoxification genes. Mol Pharmacol 2005; 67: 1861-73.
13. Chaney MA. Corticosteroids and cardiopulmonary bypass: a re-view of clinical investigations. Chest 2002; 121: 921-31.
14. Mallioris CN, Kounis NG. Glucocorticoids, Kounis syndrome andthe prevention of atrial fibrillation. Eur Heart J 2004; 25: 2175-6.
15. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 2003; 91: 1055-9.
16. Koutsojannis CM, Mallioris CN, Kounis NG. Corticosteroids,Kounis syndrome and the treatment of refractory vasospastic an-gina. Circ J 2004; 68: 806; author reply 807.
17. Fan WJ, Genade S, Genis A, Huisamen B, Lochner A. Dexametha-sone-induced cardioprotection: a role for the phosphatase MKP-1? Life Sci 2009; 84: 838-46.
18. Viegas LR, Hoijman E, Beato M, Pecci A. Mechanisms involved intissue-specific apopotosis regulated by glucocorticoids. J SteroidBiochem Mol Biol 2008; 109: 273-8.
19. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpressionof iNOS in mice results in peroxynitrite generation, heart block,and sudden death. J Clin Invest 2002; 109: 735-43.
20. Ferdinandy P, Schulz R. Peroxynitrite: toxic or protective in theheart? Circ Res 2001; 88: E12-3.
21. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in theregulation of transcription factors that control cytokine synthesis.Cytokine Growth Factor Rev 2007; 18: 45-56.
22. Gonnella PA, Waldner H, Del Nido PJ, McGowan FX. Inhibitionof experimental autoimmune myocarditis: peripheral deletion ofTcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR-4 deficient mice. JAutoimmun 2008; 31: 180-7.
23. Beck IM, Berghe WV, Gerlo S, et al. Glucocorticoids and mitogen-and stress-activated protein kinase 1 inhibitors: possible partners inthe combat against inflammation. Biochem Pharmacol 2009; 77:1194-205.
24. Wiegers GJ, Reul JM. Induction of cytokine receptors by glucocor-ticoids: functional and pathological significance. Trends Pharmacol Sci 1998; 19: 317-21.
25. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticos-teroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-9.
26. Negoro S, Oh H, Tone E, et al. Glycoprotein 130 regulates cardiacmyocyte survival in doxorubicin-induced apoptosis through phos-phatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001; 103: 555-61.
27. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardio-vascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. NatMed 2002; 8: 473-9.
28. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B,Rosenzweig A. Serum and glucocorticoid-responsive kinase-1regulates cardiomyocyte survival and hypertrophic response. Circu-lation 2005; 111: 1652-9.
29. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC,Zuraw BL. The anti-inflammatory effect of glucocorticoids is me-diated by glucocorticoid-induced leucine zipper in epithelial cells. JAllergy Clin Immunol 2007; 119: 115-22.
30. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduc-tion of experimental myocardial infarct size by corticosteroid ad-ministration. J Clin Invest 1973; 52: 599-607.
31. Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E.Mummification of the infarcted myocardium by high dose corticos-teroids. Circulation 1978; 57: 56-63.
32. Madias JE, Hood WB, Jr. Effects of methylprednisolone on theischemic damage in patients with acute myocardial infarction. Cir-culation 1982; 65: 1106-13.
33. Barzilai D, Plavnick J, Hazani A, Einath R, Kleinhaus N, Kanter Y.Use of hydrocortisone in the treatment of acute myocardial infarc-tion. Summary of a clinical trial in 446 patients. Chest 1972; 61:488-91.
34. Hammerman H, Kloner RA, Hale S, Schoen FJ, Braunwald E.Dose-dependent effects of short-term methylprednisolone on myo-cardial infarct extent, scar formation, and ventricular function. Cir-culation 1983; 68: 446-52.
35. Bush CA, Renner W, Boudoulas H. Corticosteroids in acute myo-cardial infarction. Angiology 1980; 31: 710-4.
36. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corti-costeroids and mortality in COPD. Chest 2006; 130: 640-6.
37. Sin DD, Paul Man SF. Cooling the fire within: inhaled corticoster-oids and cardiovascular mortality in COPD. Chest 2006; 130: 629-31.
38. Suissa S, Assimes T, Brassard P, Ernst P. Inhaled corticosteroid usein asthma and the prevention of myocardial infarction. Am J Med 2003; 115: 377-81.
39. de Vries F, Pouwels S, Bracke M, et al. Use of inhaled corticoster-oids and the risk of non-fatal acute myocardial infarction. J Hyper-tens 2008; 26: 124-9.
40. Takagi S, Goto Y, Hirose E, et al. Successful treatment of refrac-tory vasospastic angina with corticosteroids: coronary arterial hy-peractivity caused by local inflammation? Circ J 2004; 68: 17-22.
41. Petrakopoulou P, Franz WM, Boekstegers P, Weis M. Vasospasticangina pectoris associated with Churg-Strauss syndrome. Nat ClinPract Cardiovasc Med 2005; 2: 484-489; quiz 490.
42. Azar RR, Rinfret S, Theroux P, et al. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapywith methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000; 21: 2026-32.
43. Pepine CJ, Hirshfeld JW, Macdonald RG, et al. A controlled trialof corticosteroids to prevent restenosis after coronary angioplasty.M-HEART Group. Circulation 1990; 81: 1753-61.
44. Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial ofcorticosteroids for the prevention of restenosis after intracoronarystent implantation. Am Heart J 1999; 138: 60-3.
45. Ferrante G, Niccoli G, Biasucci LM, et al. Association between C-reactive protein and angiographic restenosis after bare metal stents:an updated and comprehensive meta-analysis of 2747 patients.Cardiovasc Rev Med 2008; 9: 156-65.
46. Versaci F, Gaspardone A, Tomai F, et al. ImmunosuppressiveTherapy for the Prevention of Restenosis after Coronary ArteryStent Implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40:1935-42.
47. Jung JH, Min PK, Kim JY, et al. Systemic immunosuppressivetherapy inhibits in-stent restenosis in patients with renal allograft.Catheter Cardiovasc Interv 2006; 68: 567-73.
48. Kong DF. Steroids for restenosis: strike three! Am Heart J 1999;138: 3-4.
49. Celik T, Iyisoy A, Barindik N, Isik E. Glucocorticoids in the pre-vention of in-stent restenosis: The role of inflammation. Int J Car-diol 2008; 135: 403-5.
50. Konig A, Leibig M, Rieber J, et al. Randomized comparison ofdexamethasone-eluting stents with bare metal stent implantation inpatients with acute coronary syndrome: serial angiographic andsonographic analysis. Am Heart J 2007; 153: 979 e1-8.
51. Pesarini G, Ferrero V, Tomai F, et al. Steroid-eluting stents inpatients with acute coronary syndromes. Angiographic results ofDESIRE: Dexamethasone-Eluting Stent Italian REgistry. J InvasiveCardiol 2009; 21: 86-91.
52. Jimenez-Valero S, Santos B, Pajin F, et al. Clinical outcomes ofdexamethasone-eluting stent implantation in ST-elevation acutemyocardial infarction. Catheter Cardiovasc Interv 2007; 70: 492-7.
53. Robertson-Malt S, Afrane B, El Barbary M. Prophylactic steroids for pediatric open heart surgery. Cochrane Database Syst Rev 2007; CD005550.
54. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis inadult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119: 1853-66.
55. Tassani P. Corticosteroids during operations using cardiopulmon-ary bypass. J Clin Anesth 2000; 12: 242-7.
56. Enc Y, Karaca P, Ayoglu U, Camur G, Kurc E, Cicek S. The acutecardioprotective effect of glucocorticoid in myocardial ischemia-reperfusion injury occurring during cardiopulmonary bypass. HeartVessels 2006; 21: 152-6.
57. Ando M, Park IS, Wada N, Takahashi Y. Steroid supplementation:a legitimate pharmacotherapy after neonatal open heart surgery.Ann Thorac Surg 2005; 80: 1672-8.
58. Mott AR, Fraser CD, Jr., Kusnoor AV, et al. The effect of short-term prophylactic methylprednisolone on the incidence and sever-ity of postpericardiotomy syndrome in children undergoing cardiacsurgery with cardiopulmonary bypass. J Am Coll Cardiol 2001; 37:1700-6.
59. Shah NH, Scriven A. Post cardiac injury syndrome after uncompli-cated coronary angioplasty. J Invasive Cardiol 2009; 21: E16-7.
60. Berberich T, Haecker FM, Kehrer B, et al. Postpericardiotomysyndrome after minimally invasive repair of pectus excavatum. J Pediatr Surg 2004; 39: e1-3.
61. Wilson NJ, Webber SA, Patterson MW, Sandor GG, Tipple M,LeBlanc J. Double-blind placebo-controlled trial of corticosteroidsin children with postpericardiotomy syndrome. Pediatr Cardiol 1994; 15: 62-5.
62. Miller RH, Horneffer PJ, Gardner TJ, Rykiel MF, Pearson TA. Theepidemiology of the postpericardiotomy syndrome: a commoncomplication of cardiac surgery. Am Heart J 1988; 116: 1323-9.
63. Khan AH. The postcardiac injury syndromes. Clin Cardiol 1992;15: 67-72.
64. Soloff LA. Pericardial cellular response during the post-myocardialinfarction syndrome. Am Heart J 1971; 82: 812-6.
65. Kossowsky WA, Epstein PJ, Levine RS. Post myocardial infarctionsyndrome: an early complication of acute myocardial infarction.Chest 1973; 63: 35-40.
66. Welin L, Vedin A, Wilhelmsson C. Characteristics, prevalence, andprognosis of postmyocardial infarction syndrome. Br Heart J 1983;50: 140-5.
67. Kassanoff AH, Martirossian MG. Postpericardiotomy and post-myocardial infarction syndrome presenting as noncardiac pulmo-nary edema. Chest 1991; 99: 1410-4.
68. Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diag-nosis and management of pericardial diseases executive summary;The Task force on the diagnosis and management of pericardialdiseases of the European society of cardiology. Eur Heart J 2004;25: 587-610.
69. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis.Circulation 2005; 112: 3608-16.
70. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interven-tions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2002: CD000526.
71. Wiysonge CS, Ntsekhe M, Gumedze F, et al. Contemporary use of adjunctive corticosteroids in tuberculous pericarditis. Int J Cardiol 2008; 124: 388-90.
72. Brucato A, Maestroni S, Cumetti D, et al. Recurrent pericarditis:infectious or autoimmune? Autoimmun Rev 2008; 8: 44-7.
73. Shabetai R. Corticosteroids for recurrent pericarditis: on the road toevidence-based medicine. Circulation 2008; 118: 612-3.
74. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recur-rent pericarditis: high versus low doses: a nonrandomized observa-tion. Circulation 2008; 118: 667-71.
75. Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment withcorticosteroids attenuates the efficacy of colchicine in preventingrecurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 2005; 26: 723-7.
76. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choicetherapy for recurrent pericarditis: results of the CORE (COlchicinefor REcurrent pericarditis) trial. Arch Intern Med 2005; 165: 1987-91.
77. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition toconventional therapy for acute pericarditis: results of the COlchi-cine for acute PEricarditis (COPE) trial. Circulation 2005; 112:2012-6.
78. Naber CK, Horstkotte D, Peterson G, Erbel R. Abstracts of the 9thInternational Symposium of Modern Concepts in Endocarditis andCardiovascular Infections. Clin Res Cardiol 2007; 96: 400-56.
79. Siaperas P, Pefanis A, Iliopoulos D, et al. Evidence of less severeaortic valve destruction after treatment of experimental staphylo-coccal endocarditis with vancomycin and dexamethasone. Antimi-crob Agents Chemother 2001; 45: 3531-7.
80. Skiadas I, Pefanis A, Papalois A, et al. Dexamethasone as adjuvanttherapy to moxifloxacin attenuates valve destruction in experimen-tal aortic valve endocarditis due to Staphylococcus aureus. Antimi-crob Agents Chemother 2007; 51: 2848-54.
81. Menard GE. Establishing the diagnosis of Libman-Sacks endo-carditis in systemic lupus erythematosus. J Gen Intern Med 2008;23: 883-6.
82. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients withadvanced cardiac AL amyloidosis with oral melphalan, dexametha-sone, and thalidomide. Ann Hematol 2009; 88: 347-50.
83. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival inpatients with systemic light-chain amyloidosis and cardiac in-volvement initially ineligible for stem cell transplantation andtreated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369-73.
84. Choi JS, Hwang EN, Kim YH, et al. Improvement after thalido-mide and dexamethasone treatment for advanced cardiac amyloido-sis: a case report. Circ J 2007; 71: 1823-5.
85. Ballo P, Motto A, Corsini F, Orlandini F, Mondillo S. Early im-provement in cardiac function detected by tissue Doppler and strainimaging after melphalan-dexamethasone therapy in a 51-year oldsubject with severe cardiac amyloidosis. Int J Cardiol 2008; 130:278-82.
86. Campbell P, Murdock C. Cardiac amyloidosis--sustained clinicaland free light chain response to low dose thalidomide and corticos-teroids. Intern Med J 2006; 36: 137-9.
87. Aber CP, Jones EW. Complete heart block treated with corticostro-phin and corticosteroid. Br Heart J 1960; 22: 723-8.
88. Aber CP, Jones EW. Corticotrophin and corticosteroids in themanagement of acute and chronic heart block. Br Heart J 1965; 27:916-25.
89. Steinberg C, Levin AR, Engle MA. Transient complete heart blockfollowing percutaneous balloon pulmonary valvuloplasty: treat-ment with systemic corticosteroids. Pediatr Cardiol 1992; 13: 181-3.
90. Nussinovitch U, Shoenfeld Y. Neonatal lupus erythematosus--cardiac manifestations and atrio-ventricular conduction block.Hare fuah 2007; 146: 940-4, 998.
91. Lee LA. The clinical spectrum of neonatal lupus. Arch DermatolRes 2009; 301: 107-10.
92. Raboisson MJ, Fouron JC, Sonesson SE, Nyman M, Proulx F,Gamache S. Fetal Doppler echocardiographic diagnosis and suc-cessful steroid therapy of Luciani-Wenckebach phenomenon andendocardial fibroelastosis related to maternal anti-Ro and anti-Laantibodies. J Am Soc Echocardiogr 2005; 18: 375-80.
93. Tincani A, Nuzzo M, Motta M, Zatti S, Lojacono A, Faden D.Autoimmunity and pregnancy: autoantibodies and pregnancy inrheumatic diseases. Ann N Y Acad Sci 2006; 1069: 346-52.
94. Waltuck J, Buyon JP. Autoantibody-associated congenital heartblock: outcome in mothers and children. Ann Intern Med 1994;120: 544-51.
95. Shinohara K, Miyagawa S, Fujita T, Aono T, Kidoguchi K. Neona-tal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999; 93: 952-7.
96. Carapetis JR, Steer AC, Mulholland EK, Weber M. The globalburden of group A streptococcal diseases. Lancet Infect Dis 2005;5: 685-94.
97. Ayoub EM. Rheumatic Fever. Clinical Immunology Principles &Practice 2001; pp. 1-7.
98. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheu-matic heart disease: genetics and pathogenesis. Scand J Immunol 2007; 66: 199-207.
99. Spagnuolo M, Taranta A. Rheumatic fever in siblings. Similarity ofits clinical manifestations. N Engl J Med 1968; 278: 183-8.
100. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in theautoimmune pathogenesis of rheumatic heart disease. Autoimmu-nity 2006; 39: 31-9.
101. Guilherme L, Kalil J. Rheumatic fever: from sore throat to auto-immune heart lesions. Int Arch Allergy Immunol 2004; 134: 56-64.
102. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treat-ment for carditis in acute rheumatic fever. Cochrane Database Syst Rev 2003: CD003176.
103. Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past,present and future. J Autoimmun 2009; 33: 282-9.
104. Taneja V, David CS. Spontaneous autoimmune myocarditis andcardiomyopathy in HLA-DQ8.NODAbo transgenic mice. J Auto-immun 2009; 33: 260-9.
105. Kodama M, Okura Y, Hirono S, et al. A new scoring system topredict the efficacy of steroid therapy for patients with active myo-carditis--a retrospective study. Jpn Circ J 1998; 62: 715-20.
106. Zhao P, Sharma AC, Ren J. Pathogenesis and therapy of autoim-munity-induced dilated cardiomyopathy. Front Biosci 2009; 14:1708-15.
107. Stanton C, Mookadam F, Cha S, et al. Greater symptom durationpredicts response to immunomodulatory therapy in dilated cardio-myopathy. Int J Cardiol 2008; 128: 38-41.
108. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, MaseriA. Immunosuppressive therapy for active lymphocytic myocarditis:virological and immunologic profile of responders versus nonre-sponders. Circulation 2003; 107: 857-63.
109. Parrillo JE. Inflammatory cardiomyopathy (myocarditis): whichpatients should be treated with anti-inflammatory therapy? Circula-tion 2001; 104: 4-6.
110. Kuhl U, Schultheiss HP. Treatment of chronic myocarditis withcorticosteroids. Eur Heart J 1995; 16 (Suppl O): 168-72.
111. Maisch B, Herzum M, Hufnagel G, Bethge C, Schonian U. Immu-nosuppressive treatment for myocarditis and dilated cardiomyopa-thy. Eur Heart J 1995; 16 (Suppl O): 153-61.
112. Hia CP, Yip WC, Tai BC, Quek SC. Immunosuppressive therapy inacute myocarditis: an 18 year systematic review. Arch Dis Child 2004; 89: 580-4.
113. Allanore Y, Vignaux O, Arnaud L, et al. Effects of corticosteroidsand immunosuppressors on idiopathic inflammatory myopathy re-lated myocarditis evaluated by magnetic resonance imaging. AnnRheum Dis 2006; 65: 249-52.
114. Chen H, Liu J, Yang M. Corticosteroids for viral myocarditis.Cochrane Data base Syst Rev 2006: CD004471.
115. Agard C, Rendu E, Leguern V, et al. Churg-Strauss syndromerevealed by granulomatous acute pericarditis: two case reports anda review of the literature. Semin Arthritis Rheum 2007; 36: 386-91.
116. Hansch A, Pfeil A, Rzanny R, Neumann T, Kaiser WA. First-passmyocardial perfusion abnormalities in Churg-Strauss syndromewith cardiac involvement. Int J Cardiovasc Imaging 2009; 25: 501-10.
117. Rosenberg M, Lorenz HM, Gassler N, Katus HA, Frey N. Rapidprogressive eosinophilic cardiomyopathy in a patient with Churg-Strauss syndrome (CSS). Clin Res Cardiol 2006; 95: 289-94.
118. Buhaescu I, Williams A, Yood R. Rare manifestations of Churg-Strauss syndrome: coronary artery vasospasm, temporal artery vas-culitis, and reversible monocular blindness-a case report. ClinRheumatol 2009; 28: 231-3.
119. Shanks M, Ignaszewski AP, Chan SY, Allard MF. Churg-Strausssyndrome with myocarditis manifesting as acute myocardial infarc-tion with cardiogenic shock: case report and review of the litera-ture. Can J Cardiol 2003; 19: 1184-8.
120. McGavin CR, Marshall AJ, Lewis CT. Churg-Strauss syndromewith critical endomyocardial fibrosis: 10 year survival after com-bined surgical and medical management. Heart 2002; 87: E5.
121. Matsuo S, Sato Y, Matsumoto T, Naiki N, Horie M. Churg-Strausssyndrome presenting with massive pericardial effusion. Heart Ves-sels 2007; 22: 128-30.
122. Pela G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G.Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol 2006; 97: 1519-24.
123. Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease:aetiopathogenesis and therapeutic utility of intravenous immuno-globulin. Autoimmun Rev 2010; 9: 441-8.
124. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treat-ment, and long-term management of Kawasaki disease: a statementfor health professionals from the Committee on Rheumatic Fever,Endocarditis and Kawasaki Disease, Council on CardiovascularDisease in the Young, American Heart Association. Circulation 2004; 110: 2747-71.
125. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospectiverandomized trial of corticosteroids in primary therapy for Kawasakidisease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-341.
126. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomizedtrial of pulsed corticosteroid therapy for primary treatment of Ka-wasaki disease. N Engl J Med 2007; 356: 663-75.
127. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment ofrefractory Kawasaki disease. J Rheumatol 2006; 33: 803-9.
128. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globu-lin resistant Kawasaki disease: A comparative study of additionalimmune globulin and steroid pulse therapy. J Cardiol 2009; 53: 15-9.
129. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroidsin the initial treatment of Kawasaki disease: report of a randomizedtrial. J Pediatr 2003; 142: 611-6.
130. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T,Morikawa A. Effect of corticosteroids in addition to intravenousgamma globulin therapy on serum cytokine levels in the acutephase of Kawasaki disease in children. J Pediatr 2003; 143: 363-7.
131. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapyon coronary artery aneurysm formation in Kawasaki disease: ameta-analysis of 862 children. Pediatrics 2005; 116: 989-95.
132. Sugishita K, Togashi Y, Aizawa A, et al. Postpartum completeatrioventricular block due to cardiac sarcoidosis: steroid therapywithout permanent pacemaker. Int Heart J 2008; 49: 377-84.
133. Umetani K, Ishihara T, Yamamoto K, et al. Successfully treatedcomplete atrioventricular block with corticosteroid in a patient withcardiac sarcoidosis: usefulness of gallium-67 and thallium-201scintigraphy. Intern Med 2000; 39: 245-8.
134. Stauder NI, Bader B, Fenchel M, Kramer U, Kuhlkamp V, MillerS. Images in cardiovascular medicine. Follow-up of cardiac sarcoi-dosis by magnetic resonance imaging. Circulation 2005; 111: e158-60.
135. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants oflong-term survival in Japanese patients with cardiac sarcoidosistreated with prednisone. Am J Cardiol 2001; 88: 1006-10.
136. Hiramastu S, Tada H, Naito S, Oshima S, Taniguchi K. Steroidtreatment deteriorated ventricular tachycardia in a patient with rightventricle-dominant cardiac sarcoidosis. Int J Cardiol 2009; 132:e85-7.
137. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sar-coidosis and evaluation of the effects of steroid therapy by gadolin-ium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110: 520-7.
138. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricularremodeling by long-term corticosteroid therapy in patients withcardiac sarcoidosis. Am J Cardiol 2005; 95: 143-6.
139. Chinushi M, Mezaki T, Aoki Y, Nakagawa I, Washizuka T, Ai-zawa Y. Demonstration of transient entrainment in monomorphicsustained ventricular tachycardia associated with cardiac sarcoido-sis. Jpn Circ J 2000; 64: 635-7.
140. Hiramitsu S, Morimoto S, Uemura A, et al. National survey onstatus of steroid therapy for cardiac sarcoidosis in Japan. Sarcoido-sis Vasc Diffuse Lung Dis 2005; 22: 210-3.
141. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H.Efficacy of corticosteroids in sarcoidosis presenting with atrioven-tricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 133-7.
142. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. June, 2000. J Bone Miner Res 2005; 20: 1487-94;.
143. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardio-vascular disease. Hypertension 2000; 36: 912-6.
144. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Con-nell JM. Cortisol effects on body mass, blood pressure, and choles-terol in the general population. Hypertension 1999; 33: 1364-8.
145. Colao A, Pivonello R, Spiezia S, et al. Persistence of increasedcardiovascular risk in patients with Cushing's disease after fiveyears of successful cure. J Clin Endocrinol Metab 1999; 84: 2664-72.
146. Walker BR, Phillips DI, Noon JP, et al. Increased glucocorticoidactivity in men with cardiovascular risk factors. Hypertension 1998; 31: 891-5.
147. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do theydamage the cardiovascular system? Postgrad Med J 1994; 70: 863-70.
148. DeMaria AN. Relative risk of cardiovascular events in patientswith rheumatoid arthritis. Am J Cardiol 2002; 89: 33D-38D.
149. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence ratesof myocardial infarction and angina in women with systemic lupuserythematosus: comparison with the Framingham Study. Am JEpidemiol 1997; 145: 408-15.
150. Halpin D. Mortality in COPD: inevitable or preventable? Insightsfrom the cardiovascular arena. COPD 2008; 5: 187-200.
151. Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascu-lar disease. Heart 2004; 90: 829-30.
152. Sholter DE, Armstrong PW. Adverse effects of corticosteroids onthe cardiovascular system. Can J Cardiol 2000; 16: 505-11.
153. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S.Multiple factors contribute to the pathogenesis of hypertension inCushing's syndrome. J Clin Endocrinol Metab 1986; 62: 275-9.
154. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al.Long-term exposure to medium-dose glucocorticoid therapy asso-ciates with hypertension in patients with rheumatoid arthritis.Rheumatology (Oxford) 2008; 47: 72-5.
155. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroidsand the risk of atrial fibrillation. Arch Intern Med 2006; 166: 1016-20.
156. Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from thesodium-retaining effects of mineralocorticoids: role of ANF and in-trarenal hormone systems. Kidney Int 1989; 35: 767-77.
157. Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J,Perez-Gutthann S. Use of oral corticosteroids and the risk of acutemyocardial infarction. Atherosclerosis 2007; 192: 376-83.
158. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids byprescription is associated with subsequent cardiovascular disease.Ann Intern Med 2004; 141: 764-70.
159. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocor-ticoids and risk of cardiovascular and cerebrovascular disease in apopulation based case-control study. Heart 2004; 90: 859-65.
160. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J.Glucocorticoids and the risk for initiation of hypoglycemic therapy.Arch Intern Med 1994; 154: 97-101.
161. Ong SL, Zhang Y, Whitworth JA. Reactive oxygen species andglucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol2008; 35: 477-82.
162. Schacke H, Docke WD, Asadullah K. Mechanisms involved in theside effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
163. Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and struc-tural abnormalities in an ovine model of chronic blood pressureelevation after prenatal corticosteroid exposure: implications fordevelopment of atrial fibrillation. Eur Heart J 2006; 27: 3045-56.
164. Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medica-tions and the risk of cardiac arrhythmias. Epidemiology 2005; 16:360-6.
165. Jahangiri M, Camm AJ. Do corticosteroids prevent atrial fibrilla-tion after cardiac surgery? Nat Clin Pract Cardiovasc Med 2007; 4:592-3.
166. Dernellis J, Panaretou M. Relationship between C-reactive proteinconcentrations during glucocorticoid therapy and recurrent atrialfibrillation. Eur Heart J 2004; 25: 1100-7.
167. Halonen J, Halonen P, Jarvinen O, et al. Corticosteroids for theprevention of atrial fibrillation after cardiac surgery: a randomizedcontrolled trial. JAMA 2007; 297: 1562-7.
168. Marik PE, Fromm R. The efficacy and dosage effect of corticoster-oids for the prevention of atrial fibrillation after cardiac surgery: Asystematic review. J Crit Care 2009; 24(3): 458-63.
169. Aulakh R, Singh S. Strategies for minimizing corticosteroid toxic-ity: a review. Indian J Pediatr 2008; 75: 1067-73.
170. Saag KG, Furst DE. Major side effects of systemic glucocorti-coids.Up to date 2009; [online].
171. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adversecardiovascular effects of pulse steroid therapy: is continuous car-diac monitoring necessary? J Am Acad Dermatol 1994; 30: 768-73.
172. Dogne JM, Hanson J, de L, X, Pratico D, Pace-Asciak CR, DrionP, Pirotte B, Ruan KH. From the design to the clinical application of throm box ane modulators. Curr Pharm Des 2006; 12(8): 903-23.
173. Maki-Petaja KM, Wilkinson IB. Anti-inflammatory drugs andstatins for arterial stiffness reduction. Curr Pharm Des 2009; 15(3):290-303.
174. Radke PW, Weber C, Kaiser A, Schober A, Hoffmann R. Dex-amethasone and restenosis after coronary stent implantation: newindication for an old drug? Curr Pharm Des 2004; 10(4): 349-55.